The journal of allergy and clinical immunology. In practice
-
J Allergy Clin Immunol Pract · Mar 2018
Randomized Controlled Trial Multicenter StudyEfficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have been approved for clinical use by regulatory agencies. ⋯ In this study, AR101 demonstrated an acceptable safety profile and demonstrated clinical activity as a potential immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.
-
J Allergy Clin Immunol Pract · Mar 2018
Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.
The effect of age on asthma severity is poorly understood. ⋯ The phenotypic features of asthma differ by severity and with advancing age. With advancing age, patients with severe asthma are more obese, have greater airflow limitation, less allergen sensitization, and variable type 2 inflammation. Novel mechanisms besides type 2 inflammatory pathways may inform the severe asthma phenotype with advancing age.